Linagliptin Clonmel (Linagliptin)

Linagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood‑sugar levels after meals and during fasting.

The dosage of Linagliptin Clonmel is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not alter the dose on their own.

The safety of linagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or GLP‑1 receptor agonists. Unlike sulfonylureas, it does not stimulate insulin release independent of glucose, reducing hypoglycaemia risk. Compared with metformin, it has a neutral effect on weight and does not require dose adjustment in renal impairment.

Linagliptin Clonmel should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and keep out of reach of children.

Linagliptin Clonmel is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, hepatic injury, and bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptin is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is advised for individuals with a history of pancreatitis, severe liver disease, or those taking medications that strongly inhibit CYP3A4 without appropriate monitoring.